Substitution Of Imported Drug Baku Materials, Kimia Farma Optimizes Subsidiary Production

Photo: Doc. Antara/Kimia Farma

JAKARTA - PT Kimia Farma Tbk optimizes the use of local production of Drug Baku Materials (BBO) which aims to achieve national health independence.

Kimia Farma in collaboration with its subsidiary, PT Kimia Farma Sungwun Pharmacopia (KFSP) made a purchase of BBO to meet the needs of the company's BBO.

Kimia Farma Corporate Secretary Change Winarno Putro said KFSP will be the BBO producer who has fulfilled the certificate of Good Directed Materials Making from the Indonesian Food and Drug Supervisory Agency (BPOM).

"The signing of this cooperation agreement is a form of Kimia Farma's commitment to optimizing the use of local production raw materials for national health independence according to the 2022 HKN theme, namely Proud Domestic Health Innovation and Technology Products to Support the Transformation of the Health System," he said in a statement quoted by Antara, Friday, November 4.

In the agreement, Kimia Farma will use three types of BBO from KFSP, namely Atorvastatin, Clopidogrel, and Entecavir, and will continue with the use of other BBO products from KFSP.

With this commitment, it is hoped that it will support the government's program to substitute imported raw materials into local raw materials.

In addition, the issuer with the stock code KAEF will also continue to support pharmaceutical independence programs and medical devices in accordance with Presidential Instruction (Inpres) Number 6 of 2016 concerning the Acceleration of the Development of the Pharmaceutical Industry and Medical Devices.